Mahkam Zanganeh is CEO at Summit Therapeutics Inc. (SMMT). They have made 8 open-market trades across 1 company since 2023, most recently 2026-06-12.
8 open-market purchases totalling $124.8M since 2023, never a sale. Across 8 scored buys the stock is up 24.2% at ninety days, and 19.2 points ahead of the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| SMMT | 573,883,879 | $8.4B |
| PLSE | 725,395 | $32.2M |
| Total | $8.4B |
Shares reported on the most recent Form 4, priced at the 2026-06-12 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 38% | 50% | 63% |
| Avg Move | -1.5% | +3.7% | +24.2% |
| Alpha | -1.2% | +3.1% | +19.2% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SMMT | BUY | 2026-06-12 | 2026-06-12 | $13.12 | $50.0M | -1.1% | +6.5% | +18.4% |
| SMMT | BUY | 2026-06-04 | 2026-06-04 | $14.60 | $1.5M | -9.1% | +4.4% | -4.3% |
| SMMT | BUY | 2025-10-21 | 2025-10-23 | $18.74 | $1000K | -12.0% | -10.2% | -15.2% |
| SMMT | BUY | 2025-09-10 | 2025-09-11 | $17.68 | $11.9M | -3.4% | +15.7% | -9.5% |
| SMMT | BUY | 2024-03-26 | 2024-03-27 | $3.72 | $539K | -3.1% | -8.3% | +90.3% |
| SMMT | BUY | 2023-12-12 | 2023-12-13 | $2.07 | $10K | +7.0% | +27.6% | +77.4% |
| SMMT | BUY | 2023-03-08 | 2023-03-08 | $1.05 | $17.6M | +3.8% | -2.5% | +26.1% |
| SMMT | BUY | 2023-03-08 | 2023-03-13 | $1.05 | $42.3M | +5.6% | -3.7% | +10.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.